Inflammatory and Autoimmune Features of Inclusion-Body Myositis

Muscle Aging, Inclusion-Body Myositis and Myopathies

Volumn , Issue , 2011, Pages 146-158

  Dalakas, Marinos C ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

"X fibers"; Dermatomyositis (DM); Inducible costimulator (ICOS); Sporadic inclusion body myositis (s IBM); T cell receptor (TCR)

Indexed keywords

EID: 84864463632     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444398311.ch8     Document Type: Chapter

References (86)

1. Dalakas MC. (1991) Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 325, 1487-1498.
2. Mastalgia FL, Garlepp MJ, Phillips BA, Zilko PJ. (2003) Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 27, 407-425.
3. Lotz BP, Engel AG, Nishino H et al. (1989) Inclusion body myositis. Observations in 40 patients. Brain 112, 727-747.
4. NeedhamM, Mastaglia FL. (2007) Inclusion bodymyositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 6(7), 620-631.
5. Dalakas MC. (2010) Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol 10(3), 346-352.
6. Schmidt J, Dalakas MC. (2010) Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies. Exp Opin 4, 241-250.
7. Dalakas MC. (2006) Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology 66 (2 Suppl. 1), S33-S38.
8. Koffman BM, Rugiero M, Dalakas MC. (1998) Autoimmune diseases and autoantibodies associated with sporadic inclusion body myositis. Muscle Nerve 21, 115-117.
9. Bandrising UA, Schrender GMTH, Giphart MJ et al. (2004) Associations with autoimmune disorders and HLA Class I, and II antigens in inclusion body myositis. Neurology 63, 2396-2398.
10. McCoy AL, Bubb MR, Plotz PH, Davis JC. (1999) Inclusion body myositis long after dermatomyositis: a report of two cases. Clin Exp Rheumatol 141, 926-930.
11. Koffman BM, Sivakumar K, Simonis T et al. (1998) HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies. J Neuroimmunol 84, 139-142.
12. Sivakumar K, Semino-Mora, Dalakas MC. (1997) An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis: studies in 3 families. Brain 120, 653-661.
13. Dalakas MC, Illa I, Gallardo E, Juarez C. (1997) Inclusion body myositis and paraproteinemia: incidence and immunopathologic correlations. Ann Neurol 41, 100-104.
14. Bradshaw EM, Orihuela A, McArdel SL et al. (2007) A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 178(1), 547-556.
15. Dalakas MC, Illa I. (1995) Common variable immunodeficiency and inclusion body myositis: a distinct myopathy mediated by natural killer cells. Ann Neurol 37, 806-810.
16. Lindberg C, Persson LI, Bjorkander J, Oldfors A. (1994) Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand 89, 123-131.
17. Arahata, K, Engel AG. (1984) Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibres invaded by T cells. Ann Neurol 16, 193-208.
18. Arahata K, Engel AG. (1986) Monoclonal antibody analysis of mononuclear cells in myopathies III. Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol 19, 112-125.
19. Schmidt J, Rakocevic G, Raju R, Dalakas MC. (2004) Upregulated inducible costimulator and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity. Brain 127, 1182-1190.
20. Pruitt 2nd JN, Showalter CJ, Engel AG. (1996) Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann Neurol 39(1), 139-143.
21. Dalakas MC. (2006) Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol 2(4), 219-227.
22. Emslie-Smith AM, Arahata K, Engel AG. (1989). Major histocompatibility complex class I antigen expression, immunologicalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 20, 224-231.
23. Dalakas MC. (2004) Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis. Curr Opin Neurol 17, 561-567.
24. Dalakas MC. (2006) Sporadic inclusion body myositis: diagnosis, pathogenesis and therapeutic strategies. Nat Clin Prac Neurol 2, 437-447.
25. Goebels N, Michaelis D, Engelhardt M et al. (1996) Differential expression of perforin in muscle-infiltrating T cell in polymyositis and dermatomyositis. J Clin Invest 97, 2905-2910.
26. Wiendl H, Hohlfeld R, Kieseier BC. (2005) Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol 26, 373-380.
27. Hohlfeld R, Engel AG. (1991) Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann Neurol 29, 498-507.
28. Behrens L, Bender A, Johnson MA, Hohlfeld R. (1997) Cytotoxic mechanisms in inflammatory myopathies: co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. Brain 120, 929.
29. Schneider C, Gold R, Dalakas MC et al. (1996) MHC class I mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis. J Neuropath Exp Neurol 55, 1205-1209.
30. Nagaraju K, Casciola-Rosen L, Rosen A et al. (2000) The inhibition of apoptosis in myositis and in normal muscle cells. J Immunol 164, 5459-5465.
31. Li M, Dalakas MC. (2000) Expression of human IAPlike protein in skeletal muscle: An explanation for the rare incidence of muscle fiber apoptosis in T-cell mediated inflammatory myopathies. J Neuroimmunol 106, 1-5.
32. Karpati G, Pouliot Y, Carpenter S. (1988). Expression of immunoreactive major histocompatability complex products in human skeletal muscles. Ann Neurol 23, 64-72.
33. Mantegazza R, Hughes SM, Mitchell D et al. (1991) Modulation of MHC class II antigen expression in human myoblasts after treatment with IFN-gamma. Neurology 41, 1128.
34. Bao SS, King NJ, dos Remedios CG. (1990) Elevated MHC class I and II antigens in cultured human embryonic myoblasts following stimulation with gammainterferon. Immunol Cell Biol 68, 235-241.
35. Hohlfeld R, Engel AG. (1990) Induction of HLA-DR expression on human myoblasts with interferongamma. Am J Pathol 136, 503.
36. Roy R, Danserau G, Tremblay JP et al. (1991) Expression of major histocompatibility complex antigens on human myoblasts. Transplant Proc 23, 799.
37. Lundberg I, Brengman JM, Engel AG. (1995) Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne's dystrophy and non-weak controls. J Neuroimmunol 63, 9-16.
38. Tews DS, Goebel HH. (1996) Cytokine expression profiles in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 55, 342-347.
39. De Bleecker JL, Meire VI, Declercq W, Van Aken HE. (1999) Immunolocalization of tumor necrosis factoralpha and its receptors in inflammatory myopathies. Neuromusc Disord 9, 239.
40. Figarella-Branger D, Civate M, Bartoli C, Pellissier JF. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle and Nerve (2003) 28(6), 659-682.
41. Raju R, Vasconcelos OM, Semino-Mora C et al. (2003) Expression of interferon-gamma inducible chemokines in the muscles of patients with inclusion body myositis. J Neuroimmunol 141, 125-131.
42. Nagaraju K, Raben N, Loeffler L et al. (2000) Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA 97, 9209-9214.
43. Bender A, Behrens L, Engel AG, Hohlfeld R. (1998) Tcell heterogeneity in muscle lesions of inclusion body myositis. J Neuroimmunol 84, 86-91.
44. Fyhr IM, Moslemi AR, Mosavi AA et al. (1997) Oligoclonal expansion of muscle infiltrating T cells in inclusion body myositis. J Neuroimmunol 79, 185-189.
45. Amemiya K, Granger RP, Dalakas MC. (2000) Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time:studies in repeated muscle biopsies. Brain 123, 2030-2039.
46. Muntzing K, Lindberg C, Moslemi AR, Oldfors A. (2003) Inclusion body myositis: clonal expansions of muscle-infiltrating T cells persist over time. Scand J Immunol 58, 195-200.
47. Salajegheh M, Rakocevic G, Raju R et al. (2007) T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis. Neurology 69, 1672-1679.
48. Behrens L, Kerschensteiner M, Misgeld T et al. (1998) Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions. J Immunol 161, 5943-5951.
49. Murata K, Dalakas MC. (1999) Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNA in inflammatory myopathies. Am J Pathol 155, 453-460.
50. Wiendel H, Mitsdoerffer M, Schneider D et al. (2003) Muscle fibers and cultured muscle or cells express the B7.1/2 related costimulatory molecule ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 126, 1026-1035.
51. Dalakas MC. (2001) The molecular and cellular pathology of inflammatory muscle diseases. Curr Opin Pharmacol 1, 300-306.
52. De Bleecker JL, De Paepe B, Vanwalleghem IE, Schroder JM. (2002) Differential expression of chemokines in inflammatory myopathies. Neurology 58, 1779-1785.
53. Raju R, Dalakas MC. (2005) Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128(Pt 8) 1887-1896.
54. Choi YC, Dalakas MC. (2000) Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology 54, 65-71.
55. Salajegheh M, Raju R, Schmidt J et al. (2007) Upregulation of thrombospondin-1(TSP-1) and its binding partners, CD36 and CD47 in sporadic inclusion body myositis. J Neuroimmunol 187, 166-174.
56. Greenberg SA, Pinkus GS, Amato AA et al. (2007) Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 35, 17-23.
57. Dalakas MC. (2004) Viral related muscle disease. In: Engel AG (ed.), Myology (3rd edn). McGraw Hill, New York, pp. 1389-1417.
58. Cupler EJ, Leon-Monzon M, Miller J et al. (1996) Inclusion body myositis in HIV-I and HTLV-I infected patients. Brain 119, 1887-1893.
59. Ozden S, Gessain A, Gout O, Mikol J. (2001) Sporadic inclusion body myositis in a patient with human T cell leukemia virus type 1-associated myelopathy. Clin Infect Dis 32, 510-514.
60. Ozden S, Cochet M, Mikol J et al. (2004) Direct evidence for a chronic CD8+-T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia/lymphoma virus type 1-infected patient with sporadic inclusion body myositis. J Virol 78, 10320-10327.
61. Saito M, Higuchi I, Saito A et al. (2002) Molecular analysis of T cell clonotypes in muscle-infiltrating lymphocytes from patients with human T lymphotropic virus type 1 polymyositis. J Infect Dis 186, 1231-1241.
62. DalakasMC, RakocevicG, Shatunov A et al. (2007)IBM withHIVinfection:4newcaseswithclonalexpansionof viral-specific T cells. Ann Neurol 61, 466-475.
63. Dalakas MC, Illa I, Pezeshkpour GH et al. (1990) Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 332, 1098-1105.
64. Fidzianska A, Rowinska-Marcinska K, Hausmanowa- Petrusewicz I. (2004) Coexistence of X-linked recessive Emery-Dreifuss muscular dystrophy with inclusion body myositis-like morphology. Acta Neuropathol 104, 197-203.
65. Semino-Mora C, Dalakas MC. (1988) Rimmed vacuoles with B-Amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (post-poliomyelitis muscular atrophy): similarities with inclusion body myositis. Hum Pathol 29, 1128-1133.
66. Selcen D, Ohno K, Engel AG. (2004) Myofibrillar myopathy: clinical, morphological and genetic studies in 63 patients. Brain 127, 439-451.
67. Ferrer I, Martin B, Castano JG et al. (2004) Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol 63, 484-498.
68. Ferrer I, Carmona M, Blanco R et al. (2005) Involvement of clusterin and the aggresome in abnormal protein deposits in myofibrillar myopathies and inclusion body myositis. Brain Pathol 15, 101-108.
69. Fratta P, Engel WK, McFerrin J et al. (2005) Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in AbPP-overexpressing cultured human muscle fibers. Am J Pathol 167, 517-526.
70. Nogalska A, D'Agostino C, Terracioano C et al. (2010) Impaired autophagy in sporadic inclusion-body myositis and in endoplasmic reticulum stress-provoked cultured human muscle fibers. Am J Pathol 177(3), 1377-1387.
71. Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, Dalakas MC. (2008) Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 131, 1228-1240.
72. Dalakas MC. (2008) Molecular links between inflamationanddegeneration: Lessonson"Neuroinflammation" using IBMas a model. Ann Neurol 64, 1-3.
73. Kitazawa M, Trinh DN, LaFerla FM. (2008) Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol 64(1), 15-24.
74. Banwell BL, Engel AG. (2000). AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 54(5), 1020-1021.
75. Muth IE, Barthel K, Bahr M et al. (2009) Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of alphaB-crystallin is associated with amyloid precursor protein and accumulation of beta-amyloid. J Neurol Neurosurg Psychiatry 80(12), 1344-1349.
76. Wojcik S, Engel WK, McFerrin J et al. (2006) AbPP overexpression & proteasome inhibition increase aBcrystallin in cultured human muscle: relevance to inclusion-bodymyositis. NeuromuscDisord 16, 839-844.
77. Dalakas MC. (2003) Therapeutic strategies in inflammatory myopathies. Semin Neurol 23, 199-206.
78. DalakasMC, Sekul EA, Cupler EJ, Sivakumar K. (1997) The efficacy of high dose intravenous immunoglobulin (IVIg) in patients with inclusion-body myositis (IBM). Neurology 48, 712-716.
79. Dalakas MC. (2010) Advances in the treatment of myositis. Nat Rev Rheumatol 6, 129-137.
80. Cherin P, Pelletier S, Teixeira A et al. (2002) Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 58, 326.
81. Layzer R, Lee HS, Iverson D, Margeta M. (2009) Dermatomyositis with inclusion body myositis pathology. Muscle Nerve 40(3), 469-471.
82. DalakasMC, Rakocevic G, Schmidt J et al. (2009) Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 132(Pt 6) 1536-1544.
83. Hughes RA, Dalakas MC, Cornblath DR et al. (2009) Clinical applications of intravenous immunoglobulins in neurology. Clin Exp Immunol 158 (Suppl. 1), 34-42.
84. Relkin NR, Szabo P, Adamiak B et al. (2009) 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 30(11), 1728-1736.
85. Fillit H, Hess GHill J et al. (2009) IV immunoglobulin is associated with reduced risk of Alzheimer disease and related disorders. Neurology 73, 180-185.
86. Dalakas MC. (2008) IVIG in other autoimmune neurological disorders: current status and future prospects. J Neurol 255 (Suppl. 3), 12-16.